Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Read Project

 44

 FINISHED 
MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combi ...
Read Project

 13

 FINISHED 

PET Imaging in Drug Design and Development (PET3D)

Start date: Jun 1, 2016, End date: May 31, 2020,

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and i ...
Read Project

 8

 FINISHED 
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Read Project

 26

 FINISHED 

Zoonotic Anticipation and Preparedness Initiative (ZAPI)

Start date: Mar 1, 2015, End date: Feb 29, 2020,

Emerging infectious diseases are occurring at increasing frequency in Europe and other regions of the world, having profound impacts on public and/or veterinary health as well as disruptive effects on sector, regional or even global economy. The predominantly zoonotic nature of emerging pathogens calls for a One Health approach uniting the human medical and veterinary fields, dedicated to swiftly ...
Read Project

 21

 FINISHED 
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Read Project

 23

 FINISHED 

European Gram Negative Antibacterial Engine (ENABLE)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Read Project

 42

 FINISHED 
...to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed up in a consortium comprising 5 partners from industry (AstraZeneca, GlaxoSmithKline, UCB, Lead Disocvery Center, Taros Chemicals) and 6 partners from academia (Universities of Dundee, Eindhoven, Leeds, Lille, Prague, and Siena). The scientific objective o ...
Read Project

 10

 FINISHED 

Accelerated Early staGe drug diScovery (AEGIS)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia.The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cros ...
Read Project

 11

 FINISHED 

Big Data in Chemistry (BIGCHEM)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

The advent of the big data era in chemistry and the life sciences requires the development of new computational analysis methods, which are not only of scientific, but also economic relevance. Currently, the international data market already grows six times faster than the entire IT sector, and growth rates further increase. Achieving and sustaining a leadership positions in the big data arena rep ...
Read Project

 9

 FINISHED 

Combatting Bacterial Resistance in Europe (COMBACTE-NET)

Start date: Jan 1, 2013, End date: Dec 31, 2019,

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Read Project

 38

 FINISHED 

ISOTOPIC LABELING FOR DRUG INNOVATION (ISOTOPICS)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occu ...
Read Project

 8

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 
This cross-disciplinary Marie Curie Innovative Training Network builds upon the transformative opportunities created by existing X-ray sources and new sources soon to be operative in Europe. These opportunities include using ultrafast X-ray sources to extract time-dependent structural information from proteins; and revolutionary possibilities created by X-ray Free Electron Laser radiation for an e ...
Read Project

 9

 FINISHED 

Exascale Compound Activity Prediction Engine (ExCAPE)

Start date: Sep 1, 2015, End date: Aug 31, 2018,

Scalable machine learning of complex models on extreme data will be an important industrial application of exascale computers. In this project, we take the example of predicting compound bioactivity for the pharmaceutical industry, an important sector for Europe for employment, income, and solving the problems of an ageing society. Small scale approaches to machine learning have already been trial ...
Read Project

 10

 FINISHED 
"Organofluorine chemistry has played a significant role in the majority of the spectacular scientific and technological developments of thepast century although this is not widely recognised even by the scientific community. Fluoroorganic molecules are key components in anever increasing number of high-value commercially important products particularly in the life science industries. The use of fl ...
Read Project

 9

 FINISHED 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Read Project

 28

 FINISHED 

European Lead Factory (EUC²LID)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Read Project

 34

 FINISHED 
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project

 21

 FINISHED 
Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 
IN-SENS is an interdisciplinary, cutting-edge European industry-academia collaborative effort for a novel training of scientists in molecular psychiatry with the prospect of discovering the biology of schizophrenia and actively promote drug discovery. Mental illnesses are a major burden to patients, relatives, and public health worldwide. IN-SENS therefore aims to profoundly change the academic-in ...
Read Project

 16

 FINISHED 

Female Investigators in Nonlinear Optical Nanoscopy - FINON (FINON)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

The aim of this ITN is to take the category of Nonlinear Optical Microscopy (NOM) techniques into the nano-dimension, allowing for label-free three-dimensional (3D), dynamic imaging of macromolecular arrangements and nanostructures by probing inherent higher-order electronic and molecular vibrations with novel detection concepts. Specific S&T objectives are to (A) explore the use of nano-sized sca ...
Read Project

 6

 FINISHED 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Start date: Oct 1, 2014, End date: Sep 30, 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Read Project

 27

 FINISHED 

Phylogenetic exploration of medicinal plant diversity (MedPlant)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

The MedPlant network will train young researchers in career enhancing approaches and techniques in biodiversity driven drug lead discovery, complimentary and entrepreneurial skills relevant for work in the pharmaceutical industry, regulatory bodies, NGOs and academia. The aim is to improve the students’ chances of employment and to strengthen Europe's research base through a collaborative training ...
Read Project

 10

 FINISHED 
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

Oral biopharmaceutics tools (ORBITO)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Read Project

 28

 FINISHED 
"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The int ...
Read Project

 13

 FINISHED 

Recognising Adverse Drug Reactions (WEB-RADR)

Start date: Sep 1, 2014, End date: Aug 31, 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project

 20

 FINISHED 

BeTheCuRE (BTCURE)

Start date: Apr 1, 2011, End date: Mar 31, 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Read Project

 41

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project

 33

 FINISHED 
The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 
"This project forms an interdisciplinary collaborative partnership between AstraZeneca (AZ, Sweden) and the University of Warwick (UoW, UK) to train Early Stage Researchers (ESRs) in systems modelling tools and techniques enabling them to perform research projects at the forefront of international pharmacokinetic (PK) and pharmacodynamic (PD) analysis. This project will build upon extremely strong ...
Read Project

 2

 FINISHED 

European Bank for induced pluripotent Stem Cells (EBISC)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Read Project

 30

 FINISHED 
We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project

 32

 FINISHED 
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Read Project

 30

 FINISHED 
A network combining 9 academic research groups and 4 collaborating industrial companies is proposed to train the next generation of PhD students and post-doctoral researchers, in developing and applying novel experimental and theoretical methods in the NMR spectroscopy of systems containing paramagnetic metals. The assembled team, with researchers distributed throughout the EU, will investigate a ...
Read Project

 12

 FINISHED 

Membrane Protein Nanocrystallography (NanoMem)

Start date: Jan 1, 2013, End date: Dec 31, 2016,

Modern structural biology builds upon synergies between lab-bench scale science on the one hand and large scale research infrastructure on the other. NanoMem recognises the transformative opportunities that are created by current X-ray source and detector developments to impact strongly on membrane protein structure, a challenging sub-field of structural biology. We will exploit synchrotron based ...
Read Project

 11

 FINISHED 

Beta-cell function in juvenile diabetes and obesity (Beta-JUDO)

Start date: Feb 1, 2012, End date: Nov 30, 2016,

The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T2DM, which is coupled to rise in childhood obesity. Accentuated insulin secretion is observed early in young obese individuals. In many subjects insulin hypersecretion is evident when insulin sensitivity is essentially normal. Based on these observations we pr ...
Read Project

 12